Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($3.58), $2.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $442.9 million versus the consensus estimate of $379.71 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.